Arcutis Biotherapeutics Inc (NASDAQ: ARQT) is 12.92% higher on its value in year-to-date trading and has touched a low of $6.99 and a high of $17.75 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ARQT stock was last observed hovering at around $16.09 in the last trading session, with the day’s loss setting it -0.36%.
Currently trading at $15.73, the stock is 1.47% and 12.35% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.45 million and changing -2.24% at the moment leaves the stock 38.25% off its SMA200. ARQT registered 69.69% gain for a year compared to 6-month gain of 72.86%. The firm has a 50-day simple moving average (SMA 50) of $14.0012 and a 200-day simple moving average (SMA200) of $11.378125.
The stock witnessed a 22.89% loss in the last 1 month and extending the period to 3 months gives it a 4.94%, and is -7.52% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.36% over the week and 7.91% over the month.
Arcutis Biotherapeutics Inc (ARQT) has around 342 employees, a market worth around $1.87B and $196.54M in sales. Fwd P/E is 53.19. Profit margin for the company is -71.25%. Distance from 52-week low is 125.04% and -11.38% from its 52-week high. The company has generated returns on investments over the last 12 months (-52.39%).
with sales reaching $64.1M over the same period.The EPS is expected to grow by 50.00% this year, but quarterly earnings will post 53.55% year-over-year. Quarterly sales are estimated to grow 29.32% in year-over-year returns.
Arcutis Biotherapeutics Inc (ARQT) Top Institutional Holders
288.0 institutions hold shares in Arcutis Biotherapeutics Inc (ARQT), with institutional investors hold 114.38% of the company’s shares. The shares outstanding are 117.85M, and float is at 104.38M with Short Float at 14.47%. Institutions hold 112.07% of the Float.
The top institutional shareholder in the company is JENNISON ASSOCIATES LLC with over 11.57 million shares valued at $107.62 million. The investor’s holdings represent 9.3712% of the ARQT Shares outstanding. As of 2024-06-30, the second largest holder is SUVRETTA CAPITAL MANAGEMENT, LLC with 10.0 million shares valued at $93.04 million to account for 8.1021 of the shares outstanding. The other top investors are RUBRIC CAPITAL MANAGEMENT LP which holds 9.82 million shares representing 7.95% and valued at over $91.3 million, while FRAZIER LIFE SCIENCES MANAGEMENT, L.P. holds 7.1147 of the shares totaling 8.79 million with a market value of $81.7 million.
Arcutis Biotherapeutics Inc (ARQT) Insider Activity
The most recent transaction is an insider sale by Watanabe Todd Franklin. SEC filings show that Watanabe Todd Franklin sold 2,171 shares of the company’s common stock on Mar 25 ’25 at a price of $17.56 per share for a total of $38131.0. Following the sale, the insider now owns 0.93 million shares.
Arcutis Biotherapeutics Inc disclosed in a document filed with the SEC on Mar 24 ’25 that Watanabe Todd Franklinsold a total of 1,500 shares of the company’s common stock. The trade occurred on Mar 24 ’25 and was made at $17.52 per share for $26282.0. Following the transaction, the insider now directly holds 0.93 million shares of the ARQT stock.
Still, SEC filings show that on Mar 25 ’25, Watanabe Todd Franklin (Officer) Proposed Sale 2,171 shares at an average price of $17.56 for $38131.0. The insider now directly holds shares of Arcutis Biotherapeutics Inc (ARQT).
